NFκB inhibition secondary to melatonin treatment in LNCaP and 22Rv1 prostate cancer cells was repeated by Sun Liu et al., further verifying NFκB as a likely downstream target of melatonin [60]. The gene discussed is NFKB1; the disease is prostate carcinoma.